By Titik Puspa 
In a remarkable display of investor confidence and technological advancement, de-extinction startup Colossal Biosciences is reportedly in advanced discussions to secure new funding at a valuation ranging between a staggering $20 billion and $30 billion. This potential valuation surge, reported by Axios, marks a significant leap from the company’s previous $10.2 billion valuation achieved just over a year ago during its $200 million Series B funding round. The swift ascent of Colossal Biosciences underscores the burgeoning investor appetite for "deep tech" ventures that promise revolutionary solutions, even those venturing into the seemingly fantastical realm of bringing extinct species back to life.
Founded with the audacious goal of reintroducing extinct species like the woolly mammoth and the dire wolf, Colossal Biosciences has consistently positioned itself at the vanguard of genetic engineering and conservation technology. When the company first announced its ambitious dire wolf project, it sparked considerable debate regarding the ethical implications and scientific feasibility of de-extinction. However, even amidst this controversy, the underlying technological advancements were recognized as potentially transformative. The company’s ability to extract and analyze ancient DNA, coupled with sophisticated gene editing techniques and reproductive technologies, has been lauded as building a robust foundation for a wide array of biotechnological applications. This latest fundraising effort, if successful, will further validate the company’s strategic vision and its capacity to translate groundbreaking scientific research into tangible commercial value.
While the specifics of the current funding round remain undisclosed, including the lead investors and the exact capital being sought, the Axios report indicates a crucial development: Colossal Biosciences has begun generating revenue. This revenue generation is a pivotal milestone for a company that, until recently, was primarily defined by its ambitious research and development goals. The diversification of its business model appears to be paying off, moving beyond the initial de-extinction narrative to encompass broader applications of its core technologies.
Colossal co-founder and CEO Ben Lamm has previously outlined a multifaceted revenue strategy for the company. One significant avenue involves offering its advanced conservation technologies to governmental bodies and international organizations. Notably, the United Arab Emirates (UAE) has already made a substantial investment of $60 million in Colossal, according to Wired. This partnership highlights the global interest in leveraging Colossal’s expertise for ecological restoration and preservation initiatives, potentially extending beyond the de-extinction agenda to address current biodiversity crises. The UAE’s investment suggests a recognition of the practical applications of Colossal’s genetic and biotechnological capabilities in areas such as habitat restoration and species management, even for existing endangered populations.
Furthermore, Colossal Biosciences has strategically spun out several subsidiary companies, each targeting distinct market opportunities and leveraging specific aspects of the parent company’s intellectual property and technological infrastructure. These spin-offs serve not only as new revenue streams but also as incubators for specialized innovation.
Breaking, for instance, is focused on developing solutions for plastic degradation, addressing a critical environmental challenge with biotechnological approaches. While details on its funding and revenue are less prominent, its existence signals Colossal’s commitment to tackling pressing global issues through its scientific prowess.
Form Bio, a computational biology platform, has already secured significant investment, raising $30 million. This platform likely leverages Colossal’s advanced data analysis and modeling capabilities, crucial for genetic research, simulation, and the development of new biological products and therapies. The success of Form Bio indicates a strong market demand for sophisticated computational tools in the life sciences sector, a field experiencing exponential growth driven by big data and artificial intelligence.
Astromech, another notable spin-off, is an AI-driven predictive modeling company with a primary focus on biology and life sciences. This venture achieved a remarkable valuation of $2 billion in March, a testament to the perceived value of its predictive capabilities in a rapidly evolving scientific landscape. Astromech’s focus on AI and predictive modeling is particularly relevant in the current era of data-intensive biological research, where the ability to forecast biological outcomes and optimize experimental designs is paramount for accelerating discovery and development.
Perhaps one of the most intriguing and potentially lucrative aspects of Colossal’s technological portfolio is its artificial animal womb technology. Lamm has indicated plans to spin this technology out as a separate entity, with potential applications extending to human fertility treatments. In a May interview with Rolling Stone, Lamm expressed optimism that this groundbreaking technology could be ready for implementation within the next year. The development of an artificial womb represents a paradigm shift in reproductive biology, holding the promise of revolutionizing how we approach infertility and potentially even assist in the development of premature infants. The commercialization of such a technology could dwarf the valuations of even the most successful biotech firms, given its profound societal implications and broad market appeal.
Looking further into the future, Colossal Biosciences has articulated a vision for generating revenue through the sale of biodiversity credits, should it succeed in reintroducing extinct species like the woolly mammoth and the dodo bird to their native ecosystems. This concept draws parallels with the established carbon credit market, proposing a market-based mechanism to incentivize and fund conservation efforts. The creation of biodiversity credits would provide a financial framework for ecological restoration, allowing corporations and individuals to invest in the rewilding of habitats and the re-establishment of keystone species. This innovative approach could unlock significant private capital for conservation, transforming the economic landscape of ecological preservation.
The current fundraising endeavor by Colossal Biosciences occurs against the backdrop of a broader investment boom in sectors such as longevity tech, alternative energy, and other deep-tech fields. Investors are increasingly seeking out companies that are not only technologically advanced but also poised to address fundamental global challenges. Colossal’s unique position at the intersection of genetic engineering, conservation, and advanced biological technologies places it squarely within this trend, appealing to investors looking for high-impact, high-growth opportunities.
The company’s ambitious de-extinction projects, while capturing public imagination, are increasingly being viewed by the financial community as a proof-of-concept for a much wider range of applications. The genetic engineering, cellular agriculture, and reproductive technologies developed for bringing back mammoths and dire wolves have direct relevance to improving livestock, developing sustainable food sources, advancing human health, and mitigating environmental damage. This broad applicability is a key driver of the substantial valuations being discussed.
While Colossal Biosciences itself has not yet responded to requests for comment regarding the ongoing funding discussions, the reported interest from investors and the company’s demonstrated progress in revenue generation and spin-off success paint a picture of a company on an upward trajectory. The ability to attract significant capital at such a high valuation, even before achieving its most audacious goals, speaks volumes about the perceived value of its scientific breakthroughs and its strategic business development. As the field of synthetic biology and genetic engineering continues to mature, companies like Colossal Biosciences are poised to redefine industries and solve some of the world’s most pressing problems, making them compelling investment targets for the future. The potential for de-extinction remains a powerful narrative, but it is the tangible applications and diversified revenue streams that are solidifying Colossal’s position as a major player in the future of biotechnology.
